229 related articles for article (PubMed ID: 14528098)
1. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy with low doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Weyl Ben-Arush M; Ben Barak A; Bar-Deroma R; Ash S; Goldstein G; Golan H; Houri H; Waldman D; Nevo N; Bar Shalom R; Berniger A; Nevelsky A; Toren A; Yaniv I; Kuten A
Isr Med Assoc J; 2013 Jan; 15(1):31-4. PubMed ID: 23484236
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
[TBL] [Abstract][Full Text] [Related]
5. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
6. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
7. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
8. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.
Howard JP; Maris JM; Kersun LS; Huberty JP; Cheng SC; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2005 Mar; 44(3):232-9. PubMed ID: 15490487
[TBL] [Abstract][Full Text] [Related]
9. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
10. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
11. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.
Garaventa A; Bellagamba O; Lo Piccolo MS; Milanaccio C; Lanino E; Bertolazzi L; Villavecchia GP; Cabria M; Scopinaro G; Claudiani F; De Bernardi B
Br J Cancer; 1999 Dec; 81(8):1378-84. PubMed ID: 10604736
[TBL] [Abstract][Full Text] [Related]
12. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.
George SL; Falzone N; Chittenden S; Kirk SJ; Lancaster D; Vaidya SJ; Mandeville H; Saran F; Pearson AD; Du Y; Meller ST; Denis-Bacelar AM; Flux GD
Nucl Med Commun; 2016 May; 37(5):466-72. PubMed ID: 26813989
[TBL] [Abstract][Full Text] [Related]
13. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
[TBL] [Abstract][Full Text] [Related]
14. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
15. Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.
Mastrangelo S; Tornesello A; Diociaiuti L; Riccardi R; Rufini V; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):69-71. PubMed ID: 9002754
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.
Bleeker G; Schoot RA; Caron HN; de Kraker J; Hoefnagel CA; van Eck BL; Tytgat GA
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1711-7. PubMed ID: 23921531
[TBL] [Abstract][Full Text] [Related]
18. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
Johnson K; McGlynn B; Saggio J; Baniewicz D; Zhuang H; Maris JM; Mosse YP
Pediatr Blood Cancer; 2011 Dec; 57(7):1124-9. PubMed ID: 21495159
[TBL] [Abstract][Full Text] [Related]
20. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
